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ABSTRACT
Here we describe a novel strategy using multiplexes
of synthetic small interfering RNAs (siRNAs) corre-
sponding to multiple gene targets in order
to compress RNA interference (RNAi) screen size.
Before investigating the practical use of this
strategy, we first characterized the gene-specific
RNAi induced by a large subset (258 siRNAs, 129
genes) of the entire siRNA library used in this study
( 800 siRNAs,  400 genes). We next demonstrated
that multiplexed siRNAs could silence at least six
genes to the same degree as when the genes were
targeted individually. The entire library was then
used in a screen in which randomly multiplexed
siRNAs were assayed for their affect on cell viability.
Using this strategy, several gene targets that
influenced the viability of a breast cancer cell line
were identified. This study suggests that the
screening of randomly multiplexed siRNAs may
provide an important avenue towards the identifica-
tion of candidate gene targets for downstream
functional analyses and may also be useful for the
rapid identification of positive controls for use in
novel assay systems. This approach is likely to be
especially applicable where assay costs or platform
limitations are prohibitive.
INTRODUCTION
Technologies that exploit the endogenous RNA-based
gene silencing mechanism, RNA interference (RNAi),
have developed rapidly for the dissection of gene-function
relationships and as a means of furthering molecular
target analysis (1,2). The value of large, high-throughput
RNAi screens in human cells has recently been demon-
strated (3–15). However, a number of practical limitations
are associated with large RNAi screens [using either small
interfering RNAs (siRNAs) or expressed short hairpin
RNAs, termed shRNAs]. Those limitations include the
need for extensive automated liquid handling and/or the
requirement for large amounts of transfection and assay
reagents, which can make such approaches inaccessible to
many laboratories. In addition, some assay platforms are
incompatible with large-scale analysis because of the
limited number of samples that can be assayed at any one
time. Furthermore, the number of ‘hits’ in larger unbiased
screens may only correspond to a small fraction of the
total targets evaluated, retrospectively making the major-
ity of such screens superﬂuous. To address some of these
issues, strategies using pools of shRNAs labeled with
unique ‘bar codes’ have been described (16,17). Bar codes
allow for the identiﬁcation of enriched or depleted
shRNAs among treated cell populations. Unfortunately,
such a method is not applicable to synthetic siRNA-based
screens. Thus, we investigated a strategy designed to
reduce the size of synthetic siRNA-based screens. This
approach involves the use of multiplexed siRNAs directed
against multiple gene targets. Since the activity of such
multiplexes has not been studied extensively at the
molecular level, we began by characterizing the activity
of co-administered siRNAs. We found that multiplexed
siRNAs corresponding to at least six gene targets yielded
reductions in associated mRNA levels comparable to
those induced by individual siRNAs. We next examined
the usefulness of a multiplex-based strategy in a screen for
targets that negatively aﬀect the growth of a highly
tumorigenic cell line. We discovered that members of a
library comprising randomly multiplexed siRNAs exhib-
ited highly reproducible phenotypic eﬀects and permitted
the rapid identiﬁcation of candidate targets that aﬀected
cell viability. Additionally, by screening a second library,
constructed such that no two constituents of a multiplex
in the ﬁrst library were co-members in the second, we
were able to identify active multiplex members without
extensive deconvolution. We oﬀer that such a strategy
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of candidate targets, especially where assay costs or
low-throughput equipments are limiting.
MATERIALS AND METHODS
Celllines
HCT-116 colon cancer cells and MDA-MB-231 breast
cancer cells (both members of the NCI-60 cell panel) were
obtained from the NCI Developmental Therapeutics
Program (DTP) (http://dtp.nci.nih.gov/) and were
maintained in RPMI containing 5% fetal bovine serum
(FBS) at 378C in a humidiﬁed atmosphere containing
5% CO2. The cells were passaged every four to ﬁve
days. The choice of cell line for characterizing RNAi
directed against individual target genes was determined
by pre-assessing a gene’s mRNA level (assayed using
a gene-speciﬁc branched-DNA/RNA assay; see below)
to ensure suﬃcient levels for accurate measurement.
Three additional cell lines (NCI/ADR-RES, MCF10A
and MCF7) were used to analyze speciﬁc gene targets,
one gene at the mRNA level and two genes at the
protein level (see Supplementary Data for additional
details).
Transfectionof synthetic siRNAs
The synthetic siRNAs used in these studies were designed
and synthesized by Qiagen Inc., Germantown, MD, USA.
Target sequences are listed in Supplementary Table 1. For
characterization studies, each siRNA (2.5 or 5pmol) was
added to individual wells in a 96-well plate in 25mlo f
serum-free RPMI and complexed with siLentfect transfec-
tion reagent (Bio-Rad, Hercules, CA, USA) in 25mlo f
serum-free RPMI using a ﬁnal lipid:siRNA ratio of 2:1
(w/w). The resulting mixture was allowed to complex for
30min at ambient temperature. All liquid-handling
steps were automated (Qiagen Robot 8000, Qiagen,
Germantown, MD, USA). Next, cells (5000) were added
in 50ml RPMI supplemented with 10% FBS to yield
transfection mixtures consisting of 25 or 50nM siRNA in
RPMI with 5% FBS. The ﬁnal mixture was incubated
at ambient temperature for 45min before being placed
at 378C in a humidiﬁed atmosphere containing 5%
CO2. Cells were harvested 48h post-transfection for
mRNA analysis. Each siRNA was evaluated in quad-
ruplicate at both 25 and 50nM by comparing target
mRNA levels to those found in cells transfected with
either 25 or 50nM negative-control siRNA. For protein
studies, transfections were performed as described above
except that they were conducted in 6-well plates and all
reagent amounts were scaled up 30-fold. Protein studies
were conducted using 50nM siRNA. As with evaluation
at the mRNA level, protein levels were compared
with those found in cells transfected with negative-control
siRNA.
Multiplexes of siRNAs were transfected in the same
way as described for mRNA characterization studies
except that they were used at a ﬁnal concentration of 60
or 120nM (10nM of each individual siRNA) and 0.7ml
of Oligofectamine (Invitrogen, Gaithersburg, MD, USA)
was added per well as the transfection reagent. After
complex formation, 5000 MDA-MB-231 cells were added.
Analogous protocols were used for transfection of
MCF10A cells except that MCF10A growth medium
was used (see Supplementary Data). Multiplex experi-
ments were incubated for two days for mRNA analysis
and four days for cell viability analysis. Multiplexed-
siRNA screens were conducted in the interior 60 wells of
96-well plates. For cell viability, all multiplexes were
assayed in duplicate. Cell viability was assayed as
described below, and plate median values were used for
normalization to compare samples assayed on diﬀerent
plates. The arrayed screen was conducted as described for
the multipex screens. For the arrayed screen, both siRNAs
targeting a given gene were evaluated as a pair, each used
at 10nM. For deconvolution and target validation, the
two siRNAs targeting a given gene were evaluated as
a pair, each used at 10nM, and compared with cells
transfected with negative control siRNA (20nM). For
evaluation of non-speciﬁc eﬀects, the two siRNAs target-
ing a given gene were evaluated as individuals (20nM)
and compared with cells transfected with negative-control
siRNA (20nM).
RNA, DNA sequence, proteinand cell viability assays
For characterization of RNAi, gene-speciﬁc transcript
levels were measured using a branched DNA-based assay
(18) (QuantiGene Reagent System, Panomics, Fremont,
CA, USA). Brieﬂy, cells were lysed 48h after siRNA
transfection and 5–80ml of lysate was assayed, depending
on transcript abundance. Gene-speciﬁc mRNA levels were
normalized to human cyclophilin B (PPIB) mRNA levels
(probe set nts 74–432). For transcript splice variant
analysis, RNA was extracted with Trizol and cDNA
synthesized at 428C using oligo-dT/random hexamers
provided by the Thermoscript RT-PCR system
(Invitrogen). Samples for i-Cycler-based (Bio-RAD) real-
time quantitative PCR (qRT-PCR) using SYBR green as
the ﬂuorochrome and 25ml reactions were run at 958C
denaturing, 50–608C re-annealing (depending on the
requirements of the speciﬁc transcript), and 728C exten-
sion for 20–40 cycles (depending on the requirements of
the speciﬁc transcript). Genomic DNA was puriﬁed using
the Puregene DNA puriﬁcation system (Gentra System,
Minneapolis, MN, USA), and sequence analysis of DNA
or cDNA PCR products primers was run using primers
ﬂanking the sequence of interest. PCR products were size
separated by agarose gel electrophoresis and puriﬁed by
extraction with phenol and ethanol. The sequences of
DNA primers used for PCR ampliﬁcation and sequencing
are shown in Supplementary Table 2. western blot analysis
was performed as previously described (19); see
Supplementary Table 3 for the antibodies used. Multi-
array ECL assay analysis was conducted according to
manufacturer’s instructions for each protein (MesoScale
Discovery, Gaithersburg, MD, USA). The reduction of
resazurin to resofurin, read as ﬂuorescence (560Ex/
590Em), was used to assay cell viability (Cell Titer Blue
Reagent, Promega, Madison, WI, USA).
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Two-tailed Student’s t-tests and correlation analysis were
done using functions in Excel (Microsoft).
RESULTS
Most synthetic siRNAs mediate RNAi
To interpret RNAi functional data fully, some character-
ization of the RNAi mediated by any given eﬀector
molecule is useful, as the degree to which mRNA and
cognate protein levels are aﬀected will inﬂuence the
observed functional eﬀects. Consequently, we analyzed
the RNAi induced by a large subset of our siRNA library.
The targets of this library include genes with a broad
range of known and putative cancer-related functions
including classical oncogenes and tumor suppressors,
established and putative anti-cancer targets (primary and
metastatic) and proteins associated with anti-cancer
chemotherapeutic responses. Overall, we characterized
the target speciﬁc eﬀects of 258 synthetic siRNAs on
mRNA levels corresponding to 129 human genes (two
siRNAs per target) (Supplementary Table 4). To compare
relative eﬃcacies, we ranked the percentage decrease in
target mRNA as compared to levels found in cells
transfected with negative-control siRNA (Figure 1a). We
found that 64% of siRNAs mediated at least a 50%
change in mRNA levels with a median percentage
decrease in gene target mRNA levels of 69% and a
maximum of 97%. A number of characterized siRNAs (37
in total) were further examined for their aﬀect on target
protein levels using western blots and/or multi-array ECL
assays (19 proteins) (Supplementary Figure 1). In  70%
of cases, the measured decrease in protein was greater than
or equal to that observed for the corresponding decrease
in mRNA levels (Figure 1b). Notably, we identiﬁed a
number of cases where RNAi was hindered by the
presence of SNPs or uncharacterized transcript splice
variants (Supplementary Figure 2).
Molecular validation ofmultiplexed siRNAs
We next examined the feasibility of multiplexing siRNAs
in order to reduce the size of traditional screens. Although
the use of siRNA pools targeting the same gene is a
relatively common practice, only a limited number of
studies using combinations of siRNAs for the simulta-
neous targeting of more than one gene have been reported.
For example, co-administration of siRNAs has been used
to dissect the roles of Rab proteins in dense-core vesicle
exocytosis (20), and co-knockdown of FAS and HER2
has been shown to promote apoptosis synergistically in
cancer cells (21). However, in the vast majority of those
types of studies, no more than two targets were
co-silenced, and the eﬀects of siRNA co-administration
were usually characterized only at a phenotypic level.
Therefore, we set out to validate conditions for the
simultaneous knockdown of multiple targets by RNAi.
Experimental multiplexes consisting of six siRNAs direct-
ed against three unique gene targets (two siRNAs per
target) yielded silencing comparable to that exhibited by
individual siRNAs in the breast cancer cell line MDA-
MB-231 (Figure 2a). Importantly, the total siRNA
concentration was held constant for these experiments
such that the sum concentration of all multiplex members
equaled that of individually evaluated siRNAs. Similar
results were observed when multiplexing twelve siRNAs
against six gene targets (Figure 2b). Multiplexes retained
activity when using gene targets other than those
described in Figure 2 (data not shown) or when
conducting studies in other cell lines, including MCF10A
(Figure 2c).
Screening siRNA multiplexes
To see if we could use this multi-gene RNAi approach to
streamline an siRNA screen in practical terms, we
generated a library comprising 135 randomly generated
multiplexes, each of which consisted of six siRNAs
corresponding to three unique gene targets. We then
used this library in a cell viability screen of MDA-MB-231
cells. Multiplexes were evaluated at a total concentration
of 60nM (10nM of each individual siRNA) and cell
viability was assessed 96h post-transfection. The library
was screened in triplicate, twice in parallel and once in a
separate experiment using cells from a diﬀerent passage
(Figure 3a). The screens conducted in parallel exhibited
good correlation (Figure 3b), sharing 19 of the 20 multi-
plexes that ranked highest in terms of a decrease in cell
viability. The third, independent screen also showed good
correlation; 16 of the same 19 multiplexes were found
among its top 20. Furthermore, the vast majority of
multiplexes showed little activity. For example,  80% of
multiplexes exhibited cell viability within 10% of the
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Figure 1. Quantiﬁcation and analysis of the RNAi mediated by
synthetic siRNAs targeting over 100 human genes. (a) A ranking of
the percentage silencing mediated by 258 siRNAs corresponding to 129
human genes. The percentage silencing was determined by comparing
the mRNA levels for each gene following transfection with 50nM
target-speciﬁc siRNA to levels found in cells transfected with 50nM
negative-control siRNA. Data is shown as the mean percentage
decrease in target mRNA levels observed for four independent parallel
transfections (plus SD). Analysis was conducted in HCT-116
(118 siRNAs), MDA-MB-231 (138 siRNAs) and NCI/ADR-RES
(two siRNAs). (b) The percentage decrease in mRNA and protein
levels for 19 genes (two siRNAs per gene). mRNA levels were measured
48h post-transfection, whereas total protein levels were measured
48–96h post-transfection.
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approach enabled us to streamline a screen of over 800
siRNAs to an extent that required no automated liquid-
handling steps. A deconvolution established the top four
gene targets responsible for reduced cell viability in the
overall screen (Figure 3c, Multiplexes A–D). Deconvolu-
tion also identiﬁed multiplexes whose activity seemingly
had not arisen from the action of a single multiplex
constituent, but rather through some cumulative eﬀect of
multiple members (Figure 3c, Multiplexes E and F).
The useof constrained multiplexed siRNA libraries
To help identify gene target(s) within any given multiplex
that contribute to the assayed phenotype without addi-
tional deconvolution, we generated a second random
library with the constraint that no two targets contained
within a multiplex in the ﬁrst library were co-members of
a multiplex in the second. Evaluation of both libraries
in MDA-MB-231 cells permitted easy identiﬁcation of
the key gene targets that markedly decreased cell
viability (Figure 4). Several of the genes identiﬁed in the
screen are highly relevant targets of anti-cancer therapeu-
tic strategies. Examples are the ribonucleotide reductase
enzyme, both subunits of which were identiﬁed here
(RRM1 and RRM2) (22), the Rho-GTPases (RHOA)
(23), polo-like kinase 1 (PLK1) (24), mTOR (FRAP1) (25)
and MEK1 (26). Other genes identiﬁed have been
proposed as targets but, often because of the diﬃculty in
developing inhibitors, have not been studied as fully.
An example is MMP2 (27). Although this strategy
represents only a modest reduction in the total screen
size as compared to screening individual siRNAs in an
arrayed format, it was again accomplished without
automated liquid handling and may be especially applic-
able if multiplexes comprising a greater number of
constituents (e.g. six gene targets per multiplex) are used.
Comparing multiplex and arrayed screens
To help examine the occurrence of false-negative results
in multiplex-based screening, we conducted an arrayed
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Figure 2. Multiplexed siRNAs retain comparable eﬃcacy to that exhibited by their individual counterparts. (a) Two multiplexes consisting of six
siRNAs corresponding to three targets (two siRNAs per target) were evaluated for their ability to reduce cognate mRNA levels as compared to the
activity of respective individual siRNAs in MDA-MB-231 cells. Total siRNA concentrations were held constant for all experiments such that
individual siRNAs (siRNA-1 and siRNA-2) were tested at 60nM and multiplexed siRNAs were tested at an individual siRNA concentration of
10nM (60nM total). Target-speciﬁc mRNA levels were compared to those found in cells transfected with negative-control siRNA. (b) Same as in (a)
except that the multiplex consisted of twelve siRNAs corresponding to six targets. In this case, the total siRNA concentration was held constant at
120nM again using 10nM of each individual component within the multiplex. (c) Same as in (a) except that the experiments were conducted in
MCF10A cells. Similarly, multiplexes retained activity when using gene targets other than those described here or when conducting studies in
additional cell lines (data not shown).
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library. For the arrayed screen, both siRNAs targeting a
given gene were combined and evaluated at a total
concentration of 20nM (10nM of each individual
siRNA). As with the multiplex screens, cell viability was
assessed 96h post-transfection. We found that 80% of
siRNAs representing the most signiﬁcant down-regulators
of cell viability in the arrayed screen, those resulting in cell
viability greater than three SD from the median value,
were identiﬁed using a multiplexed strategy (4 of 5 genes).
This comparison helps to demonstrate that a multiplex-
based approach can identify a majority of the strongest
hits within a given synthetic siRNA library.
DISCUSSION
As the scale of an siRNA-based screen increases, the need
for automated liquid handling and large amounts of assay
reagents can become limiting for many laboratories.
Additionally, large-scale screens may be incompatible
with assays using limited capacity equipment, for example
‘high content’ screening approaches using imaged-based
phenotypic analysis. In many cases, the scale of a screen
may be increased further by the need to evaluate siRNAs
under a variety of conditions. For example, screens for
targets that aﬀect compound activity should minimally
require the evaluation of siRNAs in both the presence
and absence of compound and may optimally require
evaluation at multiple doses. Thus, strategies for reducing
screen size would be advantageous in a number of
contexts.
Multiplexed-based approaches have often been used in
small-molecule screens and in studies of protein–protein
interactions. Here we extend that strategy in order to
reduce the size of siRNA-based screens. We ﬁrst
characterized the activity of multiplexed siRNAs at a
molecular level and found that multiplexed siRNAs
reduced the mRNA levels of at least six targets
simultaneously. This is interesting as others have
reported a reduction in siRNA activity as a function of
co-transfection with inactive siRNAs (28). Our results
suggest that it is possible to achieve optimal transfection
conditions, whereby multiplexed siRNAs retain activity
comparable to that exhibited by their individual constitu-
ents in, at least, some cell lines. By validating the ability
of multiplexed siRNAs to co-regulate several genes, we
suggest that siRNA-mediated RNAi could be used more
extensively, than currently reported, for the study of
interactions within biological pathways and networks.
This type of analysis could be especially valuable for the
development of anti-cancer drugs, as it could assist in
identifying molecular target combinations that generate
particularly lethal phenotypes.
As with all RNAi-based studies, oﬀ-target eﬀects may
result in false positives. This study uses multiplexes of
siRNAs to streamline screens. The use of multiplexes
could result in a higher occurrence of oﬀ-target eﬀects. To
potentially reduce these eﬀects, we used individual
siRNAs within multiplexes at relatively low, but eﬀective,
concentrations (10nM). Some studies have demonstrated
that using siRNAs at low concentrations can reduce oﬀ-
target eﬀects. For example, lowering siRNA concentra-
tions from 100 to 20nM eliminated the oﬀ-target eﬀects
associated with 15 diﬀerent siRNAs corresponding to
three diﬀerent genes (29). Conversely, other studies have
indicated that oﬀ-target eﬀects do not simply result from
high siRNA concentrations and cannot be eliminated by
using less siRNA (30,31). Although those studies have
shown that oﬀ-target eﬀects exhibit dose responses that
mirror on-target interactions, reductions in oﬀ-target
transcripts are generally less than observed for intended
targets. Thus, their presence will not automatically result
in a phenotype, even in cases where the oﬀ-target
transcripts are relevant to the biological question under
investigation. To examine the inﬂuence of oﬀ-target eﬀects
on screen results speciﬁcally, we evaluated the two
siRNAs for each of the top ﬁve gene targets responsible
for a decrease in cell viability as individuals (Figure 4c).
For 4 of the 5 targets, both siRNAs yielded at least a
modest decrease in cell viability, suggesting that the
phenotype is target dependent. For RRM2, only one
siRNA appeared active, leaving open the possibility that
activity resulted from oﬀ-target eﬀects. However, the
inactive RRM2 siRNA was less capable of reducing
RRM2 mRNA levels (Supplementary Table 4).
Evaluation of additional siRNAs against all targets,
especially RRM2, would be necessary to conﬁrm target-
speciﬁc eﬀects with greater conﬁdence. It is important to
note that false positives arising from oﬀ-target eﬀects
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Figure 3. Comparing screen reproducibility and deconvolution.
(a) Graphical representation comparing three cell viability screens
conducted in MDA-MB-231 cells. The ﬁrst two screens (1 and 2) were
conducted in parallel, whereas the third (3) was conducted under
independent conditions. The y-axis reﬂects percent of the median value.
(b) The correlation between screens. (c) Deconvolution of the top
twenty multiplexes revealed those containing the top four reducers of
cell viability (multiplexes A–D), while also identifying multiplexes
whose ranking does not appear to result from the activity of an
individual target, but perhaps through an additive eﬀect (multiplexes E
and F). All values are reported as the percent viability of cells
transfected with a negative-control siRNA. As an additional reference,
a multiplex found to approximate the median value in all three screens
of library #1 was also used.
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arrayed format were used. Multiplexes would exhibit a
higher rate of false positives only in cases where a sum
eﬀect between multiplex members results in a measurable
phenotype. A dual library strategy would help to identify
these situations. For example, the multiplexes ranked 12
and 15 in Figure 4a are the same as the deconvoluted
multiplexes E and F in Figure 3c. Notably, the advent of
siRNA chemical modiﬁcations that reduce oﬀ-target
interactions (32) and the development of new algorithms
that include a more current understanding of oﬀ-target
interactions (e.g. avoiding microRNA-type interactions
between siRNAs and untargeted 30 UTRs (33)) may make
the use of a multiplexed strategy even more appealing.
Through the use of a library comprising randomly
generated multiplexes of siRNAs that target multiple
genes, we were able to streamline a siRNA-based screen
substantially. Both the identiﬁcation of established anti-
cancer therapeutic targets and the identiﬁcation of
siRNAs ranking highest in an analogous arrayed screen
help to validate this type of approach. Furthermore,
we found that the number of downstream experiments
required for validation could be minimized through the
use of a carefully constructed second library that
facilitated identiﬁcation of key targets with only limited
deconvolution. Although we conducted a screen using
multiplexes of siRNAs directed against three gene targets,
presumably screens could also be conducted with siRNAs
multiplexed in larger numbers, as we have demonstrated
that at least six targets can be co-silenced. To explore this
further, we conducted a screen comprising six gene
multiplexes in MDA-MB-231 cells (data not shown). We
found that 6 of the 8 multiplexes that ranked highest in
terms of a decrease in cell viability contained gene targets
ranked among the top 10 of the arrayed screen, suggesting
that it is plausible to screen larger multiplexes. However,
analogous to similar strategies using compound libraries,
multiplex size needs to be balanced with the number of
expected hits in order to limit the number of downstream
experiments necessary for deconvolution. For example,
an optimal mixture size of 15–20 compounds is predicted
for random chemical libraries exhibiting hit rates of
0.2–0.35%, whereas biased compound libraries, with hit
rates greater than 5%, have optimal pools sizes of less
than ﬁve compounds (34). Consequently, screens exhibit-
ing high hit rates may not be amenable to a random
multiplexed strategy. For example, screens biased towards
using siRNAs against related targets, such as the human
kinome, can have very high hit rates (8,13). However,
in other contexts, screens conducted with large
unbiased siRNA libraries would be expected to exhibit
low hit rates. For example, an shRNA library screen
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Figure 4. A dual library screening strategy for the identiﬁcation of targets responsible for observed phenotypes. (a) The identiﬁed members of active
siRNA multiplexes aﬀecting cell viability. These target genes were identiﬁed by cross-referencing the components of the top 20 down-regulating
multiplexes within library #1 with common components found in the top 20 down-regulators within library #2. (b) Validation of the identiﬁed targets
as down-regulators of cell viability in an independent assay. All values are reported as the percent viability of cells transfected with a negative-control
siRNA. As an additional reference, a multiplex found to approximate the median value in all three screens of library #1 was also used. (c) Evaluation
of both siRNAs against the top ﬁve gene targets individually. The experiment was performed as described in (b). The activity of RRM2 siRNA-1 did
not diﬀer from that of the median multiplex. For each target, the activity of siRNA pairs was approximately equal to that of the more active siRNA
(compare (b) with (c)).
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cant modulators of p53-dependent cell proliferation arrest
(4). Thus, a random multiplexed strategy may be
applicable to a wide variety of studies with optimal
multiplex size ultimately dependent upon expected hit
rates as well as other aspects of the assay and its aims.
Altogether, this study suggests that the screening of
randomly multiplexed siRNAs may provide an important
avenue towards the rapid identiﬁcation of candidate gene
targets for downstream functional analyses and may also
be useful for the rapid identiﬁcation of positive controls
for use in novel assay systems. A multiplex-based strategy
may be especially applicable in cases where assay costs,
platform limitations and other practical issues are
prohibitive.
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